Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05772156 · ClinicalTrials.gov registry record · Phase 4
Prophylactic Methylergonovine for Twin Cesarean
A Phase 4 study of Postpartum Hemorrhage and Twin; Complicating Pregnancy, sponsored by Columbia University.
- Completed
- Registry status
- Phase 4
- Development phase
- 66
- Enrollment target
- 1
- Study location
NCT05772156: Completed Phase 4 study of Postpartum Hemorrhage and Twin; Complicating Pregnancy, sponsored by Columbia University.
NCT05772156 is a Phase 4 study of Postpartum Hemorrhage and Twin; Complicating Pregnancy that has completed, run by Columbia University. The registered enrollment target is 66 participants, below the 777-participant average among 19 other Postpartum Hemorrhage trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05772156, a Phase 4 study of Postpartum Hemorrhage and Twin; Complicating Pregnancy, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 66 participants
- Enrollment target
- 1
- Study location
Study Summary
Obstetrical hemorrhage (excessive bleeding related to pregnancy) is a leading cause of maternal morbidity (disease or symptom of disease) and mortality (death) worldwide with a significantly higher frequency and severity following cesarean delivery. Twin gestations (twin pregnancy) are at particularly higher risk for postpartum hemorrhage, yet the management of obstetrical bleeding following twin delivery remains identical to singleton delivery. The purpose of this study is to understand the effect of prophylactic methylergonovine on blood loss in scheduled twin pregnancy cesarean deliveries. Participants will be randomized (like tossing a coin) to Methylergonovine (investigational drug) or water with salt (saline) (placebo). Methylergonovine or saline will be given as an injection immediately after delivery.
Primary Outcome
The change in maternal hemoglobin level as taken from blood samples. The change will be calculated from preoperative day 1 (baseline) to postoperative day 1.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Methylergonovine
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2023-03-07 |
| Est. Completion | 2024-03-11 |
| Phase | Phase 4 |
What the finished NCT05772156 record still lists
NCT05772156 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 777-participant average among 19 other Postpartum Hemorrhage trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Postpartum Hemorrhage appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05772156 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05772156 about?
NCT05772156 is a clinical study titled "Prophylactic Methylergonovine for Twin Cesarean". Obstetrical hemorrhage (excessive bleeding related to pregnancy) is a leading cause of maternal morbidity (disease or symptom of disease) and mortality (death) worldwide with a significantly higher frequency and severity following cesarean delivery. Twin gestations (twin pregnancy) are at particular...
What is the current status of trial NCT05772156?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 66 participants. The study started on 2023-03-07. Estimated completion is 2024-03-11.
What conditions does trial NCT05772156 study?
This clinical trial studies the following conditions: Postpartum Hemorrhage, Twin; Complicating Pregnancy.
What interventions are being tested in trial NCT05772156?
The interventions under investigation include: Placebo (DRUG), Methylergonovine (DRUG).
Who is sponsoring clinical trial NCT05772156?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05772156 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postpartum Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05772156's enrollment target sits among peer trials
66 15th of 19 higher than 5 of 19 other Postpartum Hemorrhage trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Postpartum Hemorrhage trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prospective Effect of Intravenous Ketorolac on Opioid Use, EBL and Complications Following Cesarean Delivery
COMPLETED · Phase 4
-
Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study
COMPLETED · Phase 4
-
Safety and Effectiveness of the KOKO Device to Treat Primary Abnormal Postpartum Uterine Bleeding or Hemorrhage
RECRUITING · NA
-
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
RECRUITING · Phase 3
-
Oxytocin Pharmacokinetics and Pharmacodynamics
RECRUITING · Phase 2
-
A Pragmatic Randomized Controlled Trial to Predict Postpartum Hemorrhage
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI